Navigation Links
Schering-Plough Announces Presentation of Phase II Trial Results,for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual,Meeting of The American College of Cardiology/i2 Summit

KENILWORTH, N.J., March 12, 2007 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that results of the Phase II trial of its novel oral thrombin receptor antagonist (TRA) SCH 530348 will be presented at the 2007 annual Scientific Sessions of the of Cardiology (ACC.07)/Innovation in Intervention (i2) Summit, March 24-27 in New Orleans. The Phase II trial, referred to as the Thrombin Receptor Antagonist in Percutaneous Coronary Intervention (TRA-PCI) trial, has been accepted as a late-breaker presentation.

The trial was designed to evaluate the safety and tolerability of Schering-Plough's TRA coadminstered with standard of care antithrombotic therapy (including aspirin and clopidogrel) in patients undergoing percutaneous coronary intervention (PCI). A secondary objective was to assess whether patients treated with the compound had fewer cardiovascular events such as heart attack, need for urgent coronary revascularization, or death at 60 days compared with patients treated with the standard of care.

The Phase II trial, with an abstract titled Results of a Multinational, Randomized, Double-Blind, Placebo-Controlled Study of a Novel Thrombin Receptor Antagonist SCH 530348 in Percutaneous Coronary Intervention, will be presented by the TRA-PCI investigators.

About Schering-Plough Corporation

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.sch ering-plough.com.

CONTACT: Media Contact: Lee A. Davies, +1-908-298-7127; or InvestorContact: Alex Kelly, +1-908-298-7436

Web site: http://www.schering-plough.com/

Ticker Symbol: (:SGP)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)...  Ethicon Endo-Surgery, Inc. announced today that ... a privately held medical device company that ... in operating rooms worldwide. The acquisition brings ... devices with Megadyne,s innovative portfolio of electrosurgical ... Ethicon,s goal to deliver the most comprehensive ...
(Date:1/20/2017)... , VAE, January 20, 2017 ... gestiegenen Bedarf an Nothilfe   Die internationale humanitäre ... für Hilfsgüter zu schaffen   Seine ... Premierminister der VAE sowie Herrscher von Dubai ... internationalen Stadt der Hilfe (International Humanitarian City IHC) zu ...
(Date:1/19/2017)... Jan. 19, 2017 The Global Therapy Partnering ... access to partnering deals and agreements entered into by ... partnering deals - Top deals by value - Deals ... technology type The report provides understanding and access ... the world,s leading healthcare companies. The report provides ...
Breaking Medicine Technology:
(Date:1/22/2017)... ... 2017 , ... Zifam Pinnacle, an Australian company dedicated to providing a unique ... buyers at the January ECRM Trade Show in Hilton Head, SC. , Zifam Pinnacle ... in all of its creations to help create a more traditional and natural approach ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing ... Often the results of a simple test will take days to arrive to the ... Now offers customers direct access to their lab tests, bypassing the cost and delay ...
(Date:1/21/2017)... ... 21, 2017 , ... Salveo for life, a company that distributes an effervescent ... United States as part of its presence to expand its market reach. , Using ... the productions of nasty toxins as a result of drinking alcohol, eliminating those toxins ...
(Date:1/21/2017)... ... 21, 2017 , ... Seamild, the largest manufacturer of oats in China, is ... and founder. As Oat is recognized globally as one of the healthiest cereals, XieQingkui, ... believes it is a move to sow the seed of good karma. Buddhism spirit ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Dianne Travis-Teague, the electrifying line-up of events for its annual meeting “Coming Home ... and community. “Coming Home 2017” will be held on Friday January 27 ...
Breaking Medicine News(10 mins):